PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

By sjmartinez • September 1, 2024

Yap TA, Choudhury AD, Hamilton E, Rosen LS, Stratton KL, Gordon MS, Schaer D, Liu L, Zhang L, Mittapalli RK, Zhong W, Soman N, Tolcher AW. PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors. ESMO Open. 2024 Aug 29;9(9):103653. doi: 10.1016/j.esmoop.2024.103653. Epub ahead of print. PMID: 39214047.

Tags: advanced solid tumors, epithelial–mesenchymal transition, Hematology/Oncology, metastatic castration-resistant prostate cancer, Publications, TGF-β signaling, TGF-β-R1 inhibitor

Related Posts

Feasibility of cognitive testing and ecological momentary assessments using smartphones in middle aged and older adults with insomnia

Ghadimi S, Ereso J, Kaula AJ, Taptiklis N, Cormack F, Alessi C, Martin JL, Dzierzewski JM, Naeim A, Kremen S, Te T, Fung CH. Feasibility[...]

A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO

Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Gorman S, Compton N, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson[...]

A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma

Amaral LJ, Gresham G, Kim S, Tighiouart M, Nelson TA, Welborn A, Lockshon L, Noorvash B, Rudnick JD, Irwin SA, Freedland SJ, Hu J. A[...]